MiNK Therapeutics, Inc. (INKT) Stock

MiNK Therapeutics, Inc. (INKT) is a Healthcare stock trading at $12.19 (as of 2026-08-21), with a market capitalization of $62.21M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

MiNK Therapeutics, Inc. develops and plans to commercialize allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases. Its lead candidate, AGENT-797, is being studied in Phase 1 for myeloma.

Valuation — source: SEC EDGAR (first-party)
Price$12.19
Market Cap$62.21M
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($754309.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJennifer S. Buell
Employees23
CountryUS
IPO Date2021-10-15

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Champions Oncology, Inc. (CSBR)
  • Cardiff Oncology, Inc. (CRDF)
  • eXoZymes, Inc. (EXOZ)
  • INmune Bio, Inc. (INMB)
  • ImageneBio Inc (IMA)
  • Instil Bio, Inc. (TIL)
  • Scilex Holding Company (SCLX)
  • Metagenomi, Inc. Common Stock (MGX)
INKT earnings history · INKT institutional & insider holders · INKT KPIs & operating metrics · INKT financials · INKT investor presentations & press releases · INKT SEC filings · INKT peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.